Published in Vaccine Weekly, December 27th, 2006
The company received positive feedback from FDA on the following topics:
- Nventa's proposed approach to combining HspE7 with the adjuvant Poly-ICLC;
- Nventa's proposal to submit an amendment to the original IND for the development of HspE7;
- Nventa's proposed Phase I study design in patients with cervical dysplasia (CIN), including high-grade (CIN II and CIN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.